Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Manley, S. Cowan-Jacob, E. Buchdunger, Doriano Fabbro, G. Fendrich, P. Furet, Thomas Meyer, Jürg Zimmermann (2002)Imatinib: a selective tyrosine kinase inhibitor.
European journal of cancer, 38 Suppl 5
E. Buchdunger, C. Cioffi, N. Law, D. Stover, Sayuri Ohno-Jones, B. Druker, N. Lydon (2000)Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
The Journal of pharmacology and experimental therapeutics, 295 1
K. Luersen, Scott Davis, S. Kaplan, Troy Abel, W. Winchester, S. Feldman (2012)Sticker Charts: A Method for Improving Adherence to Treatment of Chronic Diseases in Children
Pediatric Dermatology, 29
S. Geest, E. Sabaté (2003)Adherence to Long-Term Therapies: Evidence for Action
European Journal of Cardiovascular Nursing, 2
R. Nieuwlaat, N. Wilczynski, T. Navarro, Nicholas Hobson, R. Jeffery, A. Keepanasseril, T. Agoritsas, N. Mistry, A. Iorio, S. Jack, Bhairavi Sivaramalingam, E. Iserman, R. Mustafa, Dawn Jedraszewski, Chris Cotoi, R. Haynes (2008)Interventions for enhancing medication adherence.
The Cochrane database of systematic reviews, 11
J. Edmonson, R. Marks, J. Buckner, M. Mahoney (2002)Contrast of Response to Dacarbazine, Mitomycin, Doxorubicin, and Cisplatin (DMAP) Plus GM-CSF Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas
Cancer Investigation, 20
M. Mehren, Nicolas Widmer (2011)Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?
Cancer treatment reviews, 37 4
E. Hess, Meghan Knoedler, N. Shah, J. Kline, M. Breslin, M. Branda, Laurie Pencille, B. Asplin, D. Nestler, A. Sadosty, I. Stiell, H. Ting, V. Montori (2012)A Randomized Trial
G. Demetri, M. Mehren, C. Blanke, A. Abbeele, B. Eisenberg, P. Roberts, M. Heinrich, D. Tuveson, S. Singer, M. Janicek, J. Fletcher, S. Silverman, S. Silberman, R. Capdeville, B. Kiese, B. Peng, S. Dimitrijević, B. Druker, C. Corless, C. Fletcher, H. Joensuu (2002)Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
The New England journal of medicine, 347 7
R. DeMatteo, M. Heinrich, W. El-Rifai, G. Demetri (2002)Clinical management of gastrointestinal stromal tumors: before and after STI-571.
Human pathology, 33 5
Haynes Rb, E. Ackloo, N. Sahota, Mcdonald Hp, X. Yao (2008)Interventions for enhancing medication adherence (Review)
T. Alvegård, K. Hall, H. Bauer, A. Rydholm (2009)The Scandinavian Sarcoma Group
Acta Orthopaedica, 80
A. Farmer, W. Hardeman, D. Hughes, A. Prevost, Youngsu Kim, A. Craven, J. Oke, S. Boase, M. Selwood, I. Kellar, J. Graffy, S. Griffin, Stephen Sutton, A. Kinmonth (2012)An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes
BMC Family Practice, 13
Y. Morishima, M. Ogura, M. Nishimura, F. Yazaki, M. Bessho, H. Mizoguchi, S. Chiba, H. Hirai, T. Tauchi, A. Urabe, Masatomo Takahashi, K. Ohnishi, T. Yokozawa, N. Emi, M. Hirano, C. Shimazaki, S. Nakao, Y. Kawai, M. Fujimoto, H. Taguchi, I. Jinnai, R. Ohno (2004)Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia: Results of a Japanese Phase II Clinical Study
International Journal of Hematology, 80
RP DeMatteo, K Owzar, R Maki, P Pisters, M Blackstein, C Antonescu, C Blanke, G Demetri, M Mehren, K Ballman (2007)Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001
J Clin Oncol, 25
Lucien Noens, Marie-Anne Lierde, Robrecht Bock, Gregor Verhoef, Pierre Zachée, Zwi Berneman, Philippe Martiat, Philippe Mineur, Koen Eygen, K. MacDonald, Sabina Geest, Tara Albrecht, Ivo Abraham (2009)Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
Blood, 113 22
H. Joensuu, M. Eriksson, K. Hall, J. Hartmann, D. Pink, J. Schütte, G. Ramadori, P. Hohenberger, J. Duyster, S. Al-Batran, M. Schlemmer, S. Bauer, E. Wardelmann, M. Sarlomo‐Rikala, B. Nilsson, H. Sihto, O. Monge, P. Bono, R. Kallio, Aki Vehtari, M. Leinonen, T. Alvegård, P. Reichardt (2012)One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
JAMA, 307 12
C. Blanke, C. Rankin, G. Demetri, C. Ryan, M. Mehren, R. Benjamin, A. Raymond, V. Bramwell, L. Baker, R. Maki, Michael Tanaka, J. Hecht, M. Heinrich, Christopher Fletcher, J. Crowley, E. Borden (2008)Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 4
J. Blay, A. Cesne, I. Ray-Coquard, B. Bui, F. Duffaud, C. Delbaldo, A. Adenis, P. Viens, M. Ríos, E. Bompas, D. Cupissol, C. Guillemet, P. Kerbrat, J. Fayette, S. Chabaud, P. Berthaud, D. Pérol (2007)Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 9
Nadia Dowshen, L. Kuhns, Amy Johnson, B. Holoyda, R. Garofalo (2012)Improving Adherence to Antiretroviral Therapy for Youth Living with HIV/AIDS: A Pilot Study Using Personalized, Interactive, Daily Text Message Reminders
Journal of Medical Internet Research, 14
Axel Cesne, I. Ray-Coquard, B. Bui, A. Adenis, M. Ríos, F. Bertucci, F. Duffaud, C. Chevreau, D. Cupissol, A. Cioffi, J. Emile, S. Chabaud, D. Pérol, J. Blay (2010)Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
The Lancet. Oncology, 11 10
The advent of imatinib mesilate, an oral target therapy, has dramatically changed the natural history of gastrointestinal stromal tumours (GISTs). This rare neoplasm has become the paradigm of targeted therapies in solid tumours, also introducing a home-based cure concept in oncology. However, it should be retained that oral drug administration entails new and relevant management problems. Multiple studies have demonstrated the efficacy of imatinib in GISTs associated with a good toxicity profile. However, the efficacy of imatinib, according to its mechanism of action and pharmacokinetics, is closely related to daily assumption. No interruption or “jerky” assumption is permitted in order to avoid efficacy loss. Thus, the issue of treatment adherence is crucial for a successful strategy and should not be overlooked. We think that dealing with the problem means assessing a wide spectrum of not only clinical and general but also psychological and individual aspects. Furthermore, both patient and family should play an active role in the “cure process” and physicians should reduce the distance separating them from their patients due to home-based target therapy, promoting communication and consolidation of a trust-based physician–patient relationship. Several advantages have been introduced by oral target therapies in oncology. However, chronic drug administration, even if generally well tolerated, when prolonged for an undetermined time could heavily impact on patients’ quality of life. This could induce non-prescribed drug suspension, with negative impact on disease control. More studies would be necessary in order to detect real patients’ adherence, to correlate drug assumption with clinical outcome and to optimize imatinib treatment strategy.
Targeted Oncology – Springer Journals
Published: May 17, 2012
Access the full text.
Sign up today, get DeepDyve free for 14 days.